Details of the Drug

General Information of Drug (ID: DMMQ2U9)

Drug Name
VGX-3100
Indication
Disease Entry ICD 11 Status REF
Cervical Intraepithelial neoplasia 2E66.1 Phase 3 [1]
Dysplasia LB30-LD2F Phase 3 [2]
Human papillomavirus infection 1A9Y Phase 2 [3]
Vulvar intraepithelial neoplasia 2E67.10 Phase 2 [2]
Vulvar squamous intraepithelial lesion 2E66.1 Phase 2 [1]
Cross-matching ID
TTD ID
D00PMB
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human papillomavirus protein E6 (HPV E6) TTE2N95 VE6_HPV16 Modulator [4]
Human papillomavirus protein E7 (HPV E7) TT3CPZW VE7_HPV16 Modulator [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT01304524) A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3. U.S. National Institutes of Health.
4 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.